Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis

Hinde El Otmani, Rowan Frunt, Simone Smits, Arjan D. Barendrecht, Steven de Maat, Rob Fijnheer, Peter J. Lenting, Claudia Tersteeg

Blood (2024) 143 (20): 2089–2098.

https://doi.org/10.1182/blood.2023021265

Published: 2024

Includes: Supplemental data

Journal Articles

Plasmin-Cleaved Von Willebrand Factor As a Biomarker for Microvascular Thrombosis

Hinde El Otmani, Rowan Frunt, Simone Smits, Steven De Maat, Rob Fijnheer, Arjan Barendrecht, Peter J Lenting, Claudia Tersteeg

Blood (2023) 142 (Supplement 1): 5391.

https://doi.org/10.1182/blood-2023-188515

Published: 2023

Journal Articles

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Blood (2023) 142 (Supplement 1): 3090.

https://doi.org/10.1182/blood-2023-181707

Published: 2023

Journal Articles

Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

A.Vera de Jonge, Carolien Duetz, Wassilis S.C. Bruins, Erik D. van Werkhoven, Marcel Nijland, Marjolein W.M. Van Der Poel, Koen de Heer, Clara P.W. Klerk, Yorick Sandberg, Rob Fijnheer, Pim Mutseaers, Djamila E. Issa, Lara H. Böhmer, Roel J.W. Van Kampen, Otto J. Visser, Daphne de Jong, Josée M. Zijlstra, Tuna Mutis, Martine E.D. Chamuleau

Blood (2022) 140 (Supplement 1): 9298–9299.

https://doi.org/10.1182/blood-2022-163068

Published: 2022

Journal Articles

Harnessing Cell-Free DNA Biological Features for Early Treatment Response Prediction in High Grade B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3529–3531.

https://doi.org/10.1182/blood-2022-168668

Published: 2022

Journal Articles

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Blood (2022) 140 (Supplement 1): 2283–2285.

https://doi.org/10.1182/blood-2022-156085

Published: 2022

Journal Articles

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura

Blood (2020) 136 (3): 353–361.

https://doi.org/10.1182/blood.2019004221

Published: 2020

Includes: Supplemental data

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

Journal Articles

Open ADAMTS13 Conformation in Immune-Mediated Thrombotic Thrombocytopenic Purpura Is Induced By Anti-ADAMTS13 Autoantibodies and Corresponds with an Ongoing ADAMTS13 Pathology

Blood (2018) 132 (Supplement 1): 222.

https://doi.org/10.1182/blood-2018-99-113762

Published: 2018

Journal Articles

The Macrophage-Specific CD163 Is an Endocytic Receptor for Von Willebrand Factor (VWF) Cleaving Protease ADAMTS13

Fabian Verbij, MSc, Nicoletta Sorvillo, PhD, Paul Kaijen, Johana Hrdinova, MSc, Rob Fijnheer, MD PhD, Anja ten Brinke, PhD, Alexander B. Meijer, PhD, Floris P. van Alphen, BSc, Timo K. van der Berg, Dr., Jonas H. Graversen, Soren K. Moestrup, MD PhD, Jan Voorberg, PhD

Blood (2016) 128 (22): 17.

https://doi.org/10.1182/blood.V128.22.17.17

Published: 2016

Journal Articles

CD4 + T cells from patients with acquired thrombotic thrombocytopenic purpura recognize CUB2 domain-derived peptides

Fabian C. Verbij, Annelies W. Turksma, Femke de Heij, Paul Kaijen, Neubury Lardy, Rob Fijnheer, Nicoletta Sorvillo, Anja ten Brinke, Jan Voorberg

Blood (2016) 127 (12): 1606–1609.

https://doi.org/10.1182/blood-2015-10-668053

Published: 2016

Includes: Supplemental data

Journal Articles

Detection of Platelet Autoantibodies Revisited to Identify Immune Thrombocytopenia

Leendert Porcelijn, MD, Elly Huiskes, Gonda Oldert, Rob Fijnheer, MD PhD, Martin R. Schipperus, MD PhD, Jaap Jan Zwaginga, MD PhD, Masja De Haas, Prof, MD

Blood (2015) 126 (23): 1142.

https://doi.org/10.1182/blood.V126.23.1142.1142

Published: 2015

Journal Articles

ADAMTS13 Reactive CD4+ T Cells Targeting CUB-2 Domain Derived Peptides in Autoimmune Thrombotic Thrombocytopenic Purpura

Fabian Verbij, MSc, Femke de Heij, Annelies Turksma, PhD, Paul Kaijen, Rob Fijnheer, MD PhD, Nicoletta Sorvillo, PhD, Anja ten Brinke, PhD, Jan Voorberg, PhD

Blood (2015) 126 (23): 107.

https://doi.org/10.1182/blood.V126.23.107.107

Published: 2015

Journal Articles

Preferential HLA-DRB1*11–dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells

Nicoletta Sorvillo, Simon D. van Haren, Paul H. Kaijen, Anja ten Brinke, Rob Fijnheer, Alexander B. Meijer, Jan Voorberg

Blood (2013) 121 (17): 3502–3510.

https://doi.org/10.1182/blood-2012-09-456780

Published: 2013

Includes: Supplemental data

Journal Articles

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Blood (2012) 120 (21): 57.

https://doi.org/10.1182/blood.V120.21.57.57

Published: 2012

Journal Articles

Preferential HLA-DRB1*11 Dependent Presentation of CUB2 Derived Peptides by ADAMTS13 Pulsed Dendritic Cells

Nicoletta Sorvillo, Simon D. van Haren, Paul H. Kaijen, Anja ten Brinke, PhD, Rob Fijnheer, Alexander B. Meijer, Jan Voorberg, PhD

Blood (2012) 120 (21): 489.

https://doi.org/10.1182/blood.V120.21.489.489

Published: 2012

Journal Articles

The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells

Nicoletta Sorvillo, Wouter Pos, Linda M. van den Berg, Rob Fijnheer, Luisa Martinez-Pomares, Teunis B. Geijtenbeek, Eszter Herczenik, Jan Voorberg

Blood (2012) 119 (16): 3828–3835.

https://doi.org/10.1182/blood-2011-09-377754

Published: 2012

Includes: Supplemental data

Journal Articles

C-Type Lectin Receptor Mediated Immune Recognition of ADAMTS13 Promotes HLA-DRB1*11 Dependent Presentation of CUB1-2 Derived Peptides by Dendritic Cells

Nicoletta Sorvillo, Simon D van Haren, Wouter Pos, Eszter Herczenik, Rob Fijnheer, Luisa Martinez-Pomares, Teunis B Geijtenbeek, Alexander B Meijer, Jan Voorberg

Blood (2011) 118 (21): 196.

https://doi.org/10.1182/blood.V118.21.196.196

Published: 2011

Journal Articles

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

Blood (2011) 118 (21): 4110.

https://doi.org/10.1182/blood.V118.21.4110.4110

Published: 2011

Journal Articles

IgG Antibodies Directed towards a Single Antigenic Surface In the Spacer Domain of ADAMTS13 Predominate In Plasma of Patients with Acquired TTP.

Wouter Pos, Rob Fijnheer, Gestur Vidarsson, Jan Voorberg

Blood (2010) 116 (21): 1438.

https://doi.org/10.1182/blood.V116.21.1438.1438

Published: 2010

NARROW

Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis

Plasmin-Cleaved Von Willebrand Factor As a Biomarker for Microvascular Thrombosis

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

Harnessing Cell-Free DNA Biological Features for Early Treatment Response Prediction in High Grade B-Cell Lymphoma

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Open ADAMTS13 Conformation in Immune-Mediated Thrombotic Thrombocytopenic Purpura Is Induced By Anti-ADAMTS13 Autoantibodies and Corresponds with an Ongoing ADAMTS13 Pathology

The Macrophage-Specific CD163 Is an Endocytic Receptor for Von Willebrand Factor (VWF) Cleaving Protease ADAMTS13

CD4 + T cells from patients with acquired thrombotic thrombocytopenic purpura recognize CUB2 domain-derived peptides

Detection of Platelet Autoantibodies Revisited to Identify Immune Thrombocytopenia

ADAMTS13 Reactive CD4+ T Cells Targeting CUB-2 Domain Derived Peptides in Autoimmune Thrombotic Thrombocytopenic Purpura

Preferential HLA-DRB1*11–dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Preferential HLA-DRB1*11 Dependent Presentation of CUB2 Derived Peptides by ADAMTS13 Pulsed Dendritic Cells

The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells

C-Type Lectin Receptor Mediated Immune Recognition of ADAMTS13 Promotes HLA-DRB1*11 Dependent Presentation of CUB1-2 Derived Peptides by Dendritic Cells

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

IgG Antibodies Directed towards a Single Antigenic Surface In the Spacer Domain of ADAMTS13 Predominate In Plasma of Patients with Acquired TTP.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only